Week 11 - Stereotactic Flashcards
stereotactic RT
- highly precise treatment
- small targets
- high doses
treatment principles
- use of multiple non-coplanar beams or arcs
- achieves a steep dose gradient
- minimal dose to critical structures and surrounding healthy tissue
- achieves conformity
SRS
radiosurgery
- single, high dose of radiation
SRT
stereotactic radiotherapy
- treatment is delivered in more than one fraction
indications for SRS/SRT
- small tumour size
- tumour location
- pathology of tumour
- the patient
- tumour recurrence
advantages of stereo over VMAT
- minimal damage to surrounding tissue
- treat to higher doses
- treatment can be given multiple times
cranial tumour sites
- acoustic neuroma
- meningioma
- cranial metastases
- GBM (glioblastoma multiforme)
acoustic neuroma + presentation + treatment
- benign tumour of the 8th cranial nerve
presentation: hearing loss, tinnitus, balance disturbances
treatment: SRS utilised when surgery risks damage to facial nerves and hearing
- SRS 12.5Gy in 1#
meningioma + treatment (SRS and SRT)
- usually benign tumour arising from meningeal tissue
stereotactic for inoperable or small tumours
- SRS 18-20Gy
- SRT 50-60Gy @ 1.8-2Gy per #
brain metastases + treatment dose
- metastases in the brain arise from a variety of primary sites
- patients can present with 1 or many mets
stereotactic dose of 16-20Gy in 1# per met
GBM + symptoms + treatment
- highly malignant and fast growing - average survival time 12 months
symptoms: headaches, nausea, seizures, memory loss, changes in speech or personality and walking difficulties
stereotactic used at time of recurrence
- SRS 6-16Gy in 1#
MRI in SRS/SRT
- essential for all patients
- provide excellent definition of tumour volume and critical structures
CT slice thickness
1mm slices for SRT/SRS
image fusion
- CT and MRI images are fused together
- CT is always the primary image
- fusions are automatic, but must be checked
dose prescription and aims for SRS/SRT
- stereotactic plans are usually prescribed so that the 80% isodose line covers the PTV
- aiming for 99% of the PTV to be covered with the prescribed dose